Exceptionally long‐lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD‐L1: A case report

Takako Inoue,Kei Kunimasa,Motohiro Tamiya,Takahisa Kawamura,Toshiyuki Minami,Kazumi Nishino
DOI: https://doi.org/10.1111/1759-7714.15254
IF: 3.223
2024-03-03
Thoracic Cancer
Abstract:The clinical course of DT treatment after immunotherapy. We present a patient with lung adenocarcinoma showing high PD‐L1 expression and BRAF V600E mutation, who achieved a remarkable long‐term response to the combination therapy of dabrafenib and trametinib (DT treatment) after disease progression on immunotherapy. This case may provide an opportunity for clinicians to consider the order of administration of immunotherapy and molecular targeted therapy for BRAF V600E‐positive lung cancer.
oncology,respiratory system
What problem does this paper attempt to address?